Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT) to improve trial planning, site selection, and patient recruitment. The partnership aims to expand global access to biomarker-driven oncology studies, enabling faster, more targeted treatment development and patient access to personalized cancer therapies. This initiative leverages Omico's extensive genomic data and clinical network across Australia to support Fortrea's clients in oncology drug development.
Fortrea Holdings and Omico's partnership to advance biomarker-driven cancer drug development provides context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Oct 23, 2026 23:02 WIB: out of 150 priced US health-sector stocks, 42 rose and 107 fell. Notable movers include OSCR at USD 32.15 with a -3.51% change and a typical hold time of 16 days, ENVB at USD 1.41 down 3.42% with 100% buy order activity, and NUVB at USD 4.54 down 3.40% with a 7-day typical hold time.
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
With U.S. crude oil prices above $100 a barrel, investors are shifting focus to smaller companies with promising technologies and upcoming catalysts. Kraig Biocraft Laboratories shipped its first commercial spider silk yarn order, moving toward scala...
FS Bancorp, Inc. has appointed Matthew D. Mullet as a director on the boards of both the company and its bank, 1st Security Bank of Washington, effective October 22, 2026. Mullet, who has been President since 2024 and CEO since 2025-2026, brings exte...
